Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

(2021) Alexander M M Eggermont et al.   LANCET ONCOLOGY

Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019

(2020) Selma Ugurel et al.   EUROPEAN JOURNAL OF CANCER

The Effects of Obesity on Anti-Cancer Immunity and Cancer Immunotherapy

(2020) Matthew J. Woodall et al.   Cancers

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

(2020) Alexander M. M. Eggermont et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies

(2018) A. Yap et al.   BRITISH JOURNAL OF ANAESTHESIA

BMI and outcomes in melanoma: more evidence for the obesity paradox

(2018) Andrew J Hayes et al.   LANCET ONCOLOGY

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

(2018) Jennifer L McQuade et al.   LANCET ONCOLOGY

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

(2018) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Propranolol for Off-label Treatment of Patients With Melanoma

(2018) Vincenzo De Giorgi et al.   JAMA Oncology

Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice

(2017) Kathleen M. Kokolus et al.   OncoImmunology

Beta-blocker usage after malignant melanoma diagnosis and survival: a population-based nested case-control study

(2014) C. McCourt et al.   BRITISH JOURNAL OF DERMATOLOGY

β-Blocker use and all-cause mortality of melanoma patients: Results from a population-based Dutch cohort study

(2013) E. Livingstone et al.   EUROPEAN JOURNAL OF CANCER

β-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines

(2013) Silvia Moretti et al.   LABORATORY INVESTIGATION

Effect of β-Blockers and Other Antihypertensive Drugs On the Risk of Melanoma Recurrence and Death

(2013) Vincenzo De Giorgi et al.   MAYO CLINIC PROCEEDINGS

Treatment With β-Blockers and Reduced Disease Progression in Patients With Thick Melanoma

(2011) Vincenzo De Giorgi et al.   ARCHIVES OF INTERNAL MEDICINE

 -Blockers and Survival among Danish Patients with Malignant Melanoma: A Population-Based Cohort Study

(2011) S. Lemeshow et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Molecular Pathways: Beta-Adrenergic Signaling in Cancer: Figure 1.

(2011) Steven W. Cole et al.   CLINICAL CANCER RESEARCH